Safety and immunogenicity of the CIGB-247 vaccine candidate combining different antigen doses with different amounts of VSSP adjuvant or with a fixed dose of aluminum phosphate in cancer patients

Trial Profile

Safety and immunogenicity of the CIGB-247 vaccine candidate combining different antigen doses with different amounts of VSSP adjuvant or with a fixed dose of aluminum phosphate in cancer patients

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs CIGB 247 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Acronyms CENTAURO-2
  • Most Recent Events

    • 16 Jan 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top